Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”How many patients have you seen with stroke or bleeding related to warfarin in LVAD patients?
A recent trial in LVAD patients compared apixaban with warfarin over 2 years:
Lower HRAEs (stroke, bleeding, thrombosis):
12.5% vs 43% (p=0.087)
Significantly fewer transfusions:
0.69 vs 4.82 EPPY (p<0.01)
Win ratio favored apixaban:
2.30 (95% CI 0.95–5.60)
Although underpowered, the signals consistently leaned toward apixaban with no excess thrombosis or mortality observed.
Bottom line:
Apixaban is showing a promise as a safe alternative to warfarin in selected LVAD patients — larger trials are needed before changing practice.”
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine